Pfizer Sees 2025 Revenue in Line With Wall Street Views
Pfizer forecast 2025 revenue and earnings in line with market expectations, despite a $1 billion hit from the redesign of federal drug benefits.
Walmart Collaborates With Meituan to Boost China E-Commerce Sales
The U.S. retail giant has formed a strategic partnership with Meituan, and its goods will be available on the Chinese delivery company's app.
Food Fight With Kroger Spells Trouble for Albertsons
Albertsons faces daunting challenges as a stand-alone company.
Oreo Owner Mondelez Taps AI to Tweak Its Classic Snacks
The cookie- and candy-maker's R&D lab has gone into overdrive with AI, which is updating some of the company's treats and spinning out new iterations. (Human tasters still required.)
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
Biden Administration Agrees to Record $15 Billion Loan to PG&E
The Energy Department loan would finance the California utility's efforts to upgrade the power grid and reduce emissions.
Lion Electric Defaults, Seeks Bankruptcy Protection to Restructure or Sell Itself
Lion Electric said it defaulted on some of its debts and was seeking bankruptcy protection under Canadian law to give the maker of electric trucks and buses time to restructure or sell its business.
Alibaba Expects to Book $1.28 Billion Loss on Sale of Department Store
The sale comes as Alibaba has been restructuring its businesses to focus on the e-commerce sector amid intensifying competition with its Chinese rivals.
Bayer Eye Drug Shows Positive Results in Late-Stage Trial
Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for people suffering from some retinal diseases.
CVS's stock seeing worst month in decades as drug seller gets criticism from both parties
Roles of drug "middlemen" are taking punches from the right by Donald Trump and from the left by Elizabeth Warren.
(END) Dow Jones Newswires
December 17, 2024 15:00 ET (20:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Comments